Related Experiment Video
Updated: May 31, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Dopaminergic agonists in Parkinson's disease
A Alonso Cánovas1, R Luquin Piudo2, P García Ruiz-Espiga3
1Servicio de Neurología, Hospital Universitario Ramón y Cajal, Madrid, España.
Neurologia (Barcelona, Spain)
|July 5, 2011
Summary
Non-ergoline dopamine agonists (DA) offer effective Parkinson's disease (PD) treatment. These medications improve motor function and quality of life, but require monitoring for serious adverse events like impulse control disorders.
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder.
- Non-ergoline dopamine agonists (DA) are a key therapeutic class for PD management.
Purpose of the Study:
- To review the pharmacology, efficacy, and safety of pramipexole, ropinirole, and rotigotine.
- To provide practical recommendations for the clinical use of these non-ergoline DA in Parkinson's disease.
Main Methods:
- Review of pharmacological properties of pramipexole, ropinirole, and rotigotine.
- Analysis of clinical trial data on efficacy and safety in early and late Parkinson's disease.
- Evaluation of extended-release and transdermal formulations.
Main Results:
- Non-ergoline DA significantly improve motor function, delay dyskinesia, and reduce levodopa dosage in Parkinson's disease.
- Extended-release formulations and transdermal patches stabilize plasma levels and are well-tolerated.
- Serious adverse events, including impulse control disorders and sleep attacks, necessitate routine monitoring.
Conclusions:
- New non-ergoline DA represent a valuable treatment option for early and advanced Parkinson's disease.
- While generally safe, potential serious adverse effects require careful patient monitoring.
- Clinical use should consider individual patient profiles and potential side effects.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...